Adult-onset perianal Langerhans cell histiocytosis presenting as pruritus ani: a case report and review of the literature

Marah Hamdan1*, Jesse C. Qiao2 and Vid Fikfak1

Abstract
Background: Langerhans cells belong to the histiocytic system and give rise to two tumors: Langerhans cell histiocytosis and Langerhans cell sarcoma. Clinical aggressiveness and degree of atypia distinguish the two neoplasms. Langerhans cell histiocytosis can infiltrate a single or multiple organ systems and particularly affects bone, skin, and lymph nodes. Perianal cutaneous Langerhans cell histiocytosis is a rare condition in adults, with 15 cases reported in the literature.

Case: We present the case of a 50-year-old hispanic man who presented with a 9-month history of pruritus ani and a personal history of diabetes insipidus. Punch biopsy confirmed a lesion of Langerhans cells origin but could not exclude Langerhans cell sarcoma because of limited sample size. An additional biopsy was planned as well as a positron emission tomography scan to determine the extent of disease spread. While the patient failed to follow up for repeat biopsy, the positron emission tomography scan was performed and was negative for metastatic disease. A stable perianal lesion of Langerhans cell histiocytosis with benign clinical features in a 50-year-old male despite lack of treatment is extremely rare and has not been described in the literature so far. Here, we review the presentation and workup of patients with Langerhans cell histiocytosis, review the relevant literature, and discuss treatment planning.

Conclusion: Perianal Langerhans cell histiocytosis is rare, and there should be a high index of suspicion with chronic or new perianal lesions, especially in a patient with a history of diabetes insipidus. It is also important to consider the patient’s full clinical course when it is not possible to reach a definitive pathological diagnosis before management.

Keywords: Langerhans cell histiocytosis, Langerhans cell sarcoma, Perianal Langerhans histiocytosis, Case report

Introduction
Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS) both originate from Langerhans antigen-presenting cells. LCS is clinically aggressive and extremely rare with an incidence of 0.2 per 10 million adults in the US, while LCH is less aggressive and has an incidence of 8–9 and 1–2 cases per million in children and adults, respectively [1]. LCH has a wide spectrum of clinical presentations and can be limited, affecting a single system (SS-LCH), or potentially terminal, affecting multiple systems (MS-LCH) [2]. SS-LCH is present in over 60% of patients, preferentially affecting bone (85%), skin (11%), and lymph nodes (2%) [3]. MS-LCH disseminates into the liver, spleen, and bone marrow [4]. Severe MS-LCH has been associated with BRAF V600 mutation and has been treated with mercaptopurine, vinblastine, and systemic prednisone for 1 year, while mild SS-LCH has been treated with topical treatments such as nitrogen mustard or corticosteroids, or oral methotrexate. [4]. Due to its rarity, there has been no standard treatment plan for LCS, but surgical resection is an optimal option for surgical resection.

*Correspondence: marah.hamdan@ttuhsc.edu
1 Departments of Surgery, Texas Tech University Health Sciences Center, El Paso, TX, USA
Full list of author information is available at the end of the article
for localized disease, while etoposide, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (E-CHOP) multiregimen has been used for systemic disease [26]. Histologically, LCH cells are 12–15 μm in diameter and have eosinophilic cytoplasm, irregular nuclei with prominent grooves and folds, and indistinct nucleoli [3].

Adult cutaneous LCH lesions are often located on the scalp, face, and external genitalia, and most commonly affect the flexural and intertriginous area, where they can manifest as pruritic skin lesions very similar to seborrheic dermatitis. Cutaneous lesions can also appear as red or purple nodules, erythematous papules, ulcerations, and abscesses. Severe acute forms can present as necrotizing plaques with pruritic and erosive lesions [2]. Cutaneous LCH has also been previously associated with diabetes insipidus (DI), a disorder of water balance in the kidneys characterized by polyuria and failure to concentrate urine. The etiology of DI comprises different autoimmune diseases, such as sarcoidosis, Wegner’s disease, infections, primary brain tumors, and lymphoma. Among diseases, LCH is the most common cause of DI—ranging between 15% and 29.1% [21, 30].

Given the rarity of LCH and its heterogeneous presentation, information about perianal cutaneous manifestations has been limited to case reports. Reported cases describe perianal lesions and systematic manifestations in the skeletal and pulmonary systems with their respective response to chemotherapeutic agents, with most patients being under the age of 50 years [2, 5–18]. Nevertheless, minimal information exists about natural LCH progression without treatment and disease management when an initial biopsy cannot exclude LCS in cases where patients are either not surgical candidates or not able to obtain surgical follow-up, limiting the ability to confirm underlying pathology. Here we describe the case of a 50-year-old Hispanic male with history of polyuria due to DI, chronic pruritus ani, and perianal ulcerations on examination who was ultimately diagnosed with LCH. We also review and compare his disease process with existing literature.

Case presentation

A 50-year-old Hispanic male was referred to the colorectal clinic with a 9-month history of perianal itching and pain. He reported developing a rash as a result of severe itching. He was previously diagnosed with diabetes insipidus (DI) of unknown etiology and complained of frequent urination. He did not have any complaints of diarrhea, constipation, melena, hematochezia, changes in appetite, or weight loss. He had no family history of cancer. The patient had brain magnetic resonance imaging (MRI) in November 2017 that showed the absence of a hyperintense T1W signal of the neurohypophysis.

He also had a colonoscopy in December 2019, which revealed a polyp in the transverse colon and perianal inflammation, which prompted his referral to the colorectal clinic. The polyp’s biopsy confirmed a benign adenomatous polyp. Surgical and medical history was otherwise negative.

On examination in the office, he was found to have a small amount of thick mucoid fluid around the anus, and significant inflammation of the perianal skin with radial excoriations involving the anal verge and extending 4 cm in radius. He also had nonblanching induration of the skin of his right leg below the knee and desquamation of his right hand.

A punch biopsy was obtained at the intersection between the normal skin and the perianal rash during this initial visit. He was prescribed 1% zinc oxide cream to apply to the perianal skin for symptomatic management of pruritus three times daily. Pathology showed atypical plasmacytoid appearing cells in the deep dermis layer with mild-to-moderate nuclear atypia, mixed with a benign-appearing lymphoplasmacytic population with occasional eosinophils. The atypical cells were positive for S-100, CD1a, CD68, and Langerin, with a Ki-67 index of 50% (Figs. 1, 2, 3, 4, 5, 6, 7). These cells were negative for BRAF V600E mutations, CD3, CD20, carcinoma, and melanoma markers. Based on these results, he was diagnosed with a Langerhans cell neoplasm.

Three weeks later, the patient reported reduced pain and itching in his right lower extremity (RLE) and perianal area after using the topical zinc oxide cream. A positron emission tomography (PET) scan (Fig. 8) was also ordered to evaluate for any metastatic disease and failed to show any disease spread. Given the extent of disease that involved the anal margin, the patient would not have been a candidate for local excision as this would cause an anal stricture. The only surgical option would have been an abdominoperineal resection, committing the patient to a permanent end colostomy.

Given the localized nature of the disease, the patient was evaluated by an oncologist, who recommended local therapy with imiquimod. Of note, the patient lives in a medically underserved area, which presented specific challenges that have altered the patient’s care. This included delays in seeking and obtaining care as well as having limited resources available to facilitate surgical and medical care. Unfortunately, despite many attempts to contact the patient and prescribe this treatment, he was not able to follow up.

Discussion

Langerhans antigen-presenting cells (LCs) belong to the histiocytic system and give rise to LCH and LCS. Due to their LCs’ origin, both LCH and LCS express CD1a,
Fig. 1  Hematoxylin and eosin (H&E) stain of perianal rash punch biopsy, 20× magnification

Fig. 2  H&E stain of perianal rash punch biopsy, 100× magnification
Fig. 3  H&E stain of perianal rash punch biopsy, 400× magnification. Note the larger atypical plasmacytoid cells with mild-to-moderate nuclear pleomorphism, grooving, eosinophilic cytoplasm, and occasional mitotic figure.

Fig. 4  CD1a immunohistochemical stain, 20×, showing positivity in the Langerhans cells, extending to the base of the punch biopsy.
S100, and Langerin (CD207) proteins and show Birbeck granules on electron microscopy. LCH is benign and has a 5-year survival probability of 100% and 92% for single and multisystem disease, respectively [19, 20]. Initial treatments include topical steroids and local radiotherapy followed by systematic chemotherapy when refractory to initial measures [21]. Conversely, LCS is highly malignant and can form de novo or develop from an existing LCH. It is similar to LCH but is defined by its malignant cytological features of atypia, prominent nucleoli, and frequent mitotic figures [22]. It can disseminate into bones, lungs, spleen, gallbladder, and peritoneum; however, it can also present as a solitary skin lesion with or without lymph node involvement [23–26]. It has a bleak prognosis with a 2-year mortality of 52% and a median overall survival of 19 months [24, 27]. Surgical excision and chemotherapy are first-line treatment options for LCS [26, 28].

As the prognosis and respective treatments of LCH and LCS differ, it is important to obtain a sufficient biopsy sample to make a definitive diagnosis. Few studies have detailed specific parameters that differentiate LCS and LCH. Pileri et al.’s study of histiocytic tumors showed that LCH had mild-to-moderate nuclear atypia with benign-appearing nuclei, while LCS had frank malignant cytologic features with more prominent nucleoli [29]. Ki-67, a cellular proliferation marker, of the patient was elevated (50%), but he had mild atypia with no significant pleomorphism. This cellular morphology is consistent with a benign proliferation, but as biopsy was of limited size from the edge of the lesion, it is not possible to know the extent of cytologic malignant features, if present, and definitively exclude the possibility of LCS.

We depended on the clinical picture to guide the patient’s disease management. The patient’s perianal lesion has been stable since its eruption in June 2019, with no systematic metastasis despite the lack of chemotherapy or surgical intervention. In addition, the patient has a 3-year history of DI, which has been reported as an inaugural sign of LCH [30]. Between 10% and 16% of LCH patients have DI [30, 31]. This is due to a particular predilection of LCH to the hypothalamic–pituitary axis (HPA), where monoclonal proliferation of aberrant histiocytes accumulates in and infiltrates into the axis. MRI findings associated with DI have been described. Typically, the pituitary stalk thickens, and it can progress into a mass lesion that extends to the hypothalamus and pituitary gland, and the normal hyperintensity of the pituitary is therefore lacking [32]. In Prosch et al.’s retrospective study, DI onset preceded LCH diagnosis in 43% of patients, and in 51% of these patients, LCH could be diagnosed within 1 year of DI [30]. There was no reported association between DI and LCS in the literature [22–24, 27, 31]. Thus, the patient was diagnosed with LCH based
on his stable cutaneous lesion, history of DI, and benign cellular morphology.

We reviewed the literature and identified 15 adult patients with perianal LCH (Table 1) [2, 5–18]. The mean age was 38 years (range 18–70 years), with male predominance. LCH lesions were present from 4 months to 5 years before diagnosis, indicating a significant delay in identification and biopsy. In concordance with this case, 5/15 patients (33%) had a history of DI before LCH diagnosis, and 1/15 had it after. Patients were initially treated with antibiotics and corticosteroids, and systemic chemotherapy was started if the lesions were refractory. Three patients had surgical interventions: perianal lesion excision, diverting colostomy due to anal obliteration after a 10-year history of LCH ulcerations, and an abdominal perineal resection (APR) due to refractory perianal lesions [10, 11, 13]. Interestingly, six (40%) patients were in their thirties, two (13%) in their teens, two (13%) in their twenties, two (13%) in their forties, one (6%) in his sixties, and one (6%) in his seventies. While ample information describes LCH age distribution in children, limited information exists for adults. This provides new information regarding the age of perianal LCH presentation in adult patients.

**Conclusion**

This is a unique case of LCH, wherein the patient presented with perianal pruritus ani that was diagnosed with LCH based on benign histological findings and the overall clinical course. All reported patients with perianal LCH have either underwent surgical intervention, were treated with systemic chemotherapy, and remained stable, or had LCH metastasis to bones, lungs, thyroid, and colon (Table 1), while this patient only had DI along-side the perianal rash. Stable perianal LCH lesion with benign clinical features in a 50-year-old male despite lack of additional medical and surgical treatment has not been described in the literature so far. This case provides information about the natural progression and variability of clinical course and outcome in patients with perianal LCH, and the review highlights patients’ age distribution, length of symptoms before diagnosis, modes of treatments, and respective outcomes in patients with perianal LCH.
Fig. 7  ki-67 index, showing a proliferation index of 50%

Fig. 8  F-18 fluorodeoxyglucose (FDG)/PET scan in coronal (A) and sagittal views (B) showing physiological uptake
| Author, year       | Age in years, sex | History                          | Perianal lesion morphology                          | Perianal lesion symptoms | Perianal lesion treatment          | Intervala | Systemic involvement | Systemic treatment | Treatment outcome | Survival (follow-up time in months) |
|-------------------|------------------|----------------------------------|---------------------------------------------------|--------------------------|----------------------------------|-----------|----------------------|-------------------|------------------|-------------------------------------|
| Abdou et al. 2017 | 33 M             | Polydipsia (4 years), perianal lesions (2 years) | Perianal ulcerative plaque with raised edges oozing pus | Pain                      | Antibiotics and steroids           | –         | DI (no brain imaging obtained) | Methotrexate          | –                | –                                   |
| Mansour et al. 2017 | 32 M         | Polydipsia (10 years), Smoking | Cutaneous infiltration of anal sphincter, eroded ulcerative plaques over the anal orifice | Pain, bleeding and purulent discharge | None, only systemic | 0         | Lungs fibrosis, rectal tumor on colonoscopy, DI (no brain imaging obtained) | Vinblastine, prednisone, gemcitabine | Anal and colonic lesions, disappeared, lung fibrosis remained stable | Yes (6)               |
| Gul et al. 2017  | 36 M             | Anal fissure, two rectal surgeries | –                                                 | Pain and pressure         | Local radiotherapy               | 9 months after perianal lesions | Thyroid              | Vinblastine, prednisone, total thyroidectomy | –                | Yes (6)            |
| Bank et al. 1988 | 18 M             | Itchy scalp lesion (2 years)     | Ulceration with purulent secretions               | –                        | Antibiotics                       | 2 months after perianal lesions | Lung fibrosis and emphysema, bilateral (BL) pneumothorax, DI (no brain imaging obtained) | Vinblastine, prednisone, topical mustard, lung subsegmental resection | Persistent scalp and perianal lesions | Yes (8)              |
| Dere et al. 2016 | 45 F             | Perianal wound (1 year)          | 3-cm ulcerovegetant purulent mass                  | Pressure sensation       | Topical steroids                  | 0         | Femur and tibial lesions          | Methotrexate (MTX)       | Skin lesion healed with MTX | Yes (1 M)               |
| Chauffaille et al. 1998 | 31 F | Polydipsia (3 years), vulvar ulcers (1 year) | Granulomatous perianal and vulvar ulceration | –                        | –                                | 0         | Femur, skull, shoulder, forearm lesions, liver, oral lesions, DI, hypothalamic tumor on brain MRI | –                | –                | –                                   |
| Mittal et al. 2009 | 45 M             | Perianal ulcers (4 M)             | –                                                 | Painful perianal ulcerations | Nitrogen mustard, steroids, pentostatin. Then, surgical excision with APR and proctectomy | Prior to perianal lesions | Bone and lung | No recurrence of skin lesion post excision | –                | Yes (36)             |
| Author, year | Age in years, sex | History | Perianal lesion morphology | Perianal lesion symptoms | Perianal lesion treatment | Interval | Systemic involvement | Systemic treatment | Treatment outcome | Survival (follow-up time in months) |
|--------------|------------------|---------|---------------------------|-------------------------|--------------------------|----------|----------------------|-----------------|-----------------|-----------------------------------|
| Foster et al. 2003 [11] | 19 M | Perianal lesions (2 years), NGSY procedure | Two flat sessile perianal lesions on each buttock | Surface bleeding | Surgical excision | 11 years prior perianal lesions | Extravascular cranial mass invading cranial fossa on head computed tomography (CT) | Craniorrhaphy for mass excision. Prednisone, vincristine, mercaptopurine | No recurrence of skin lesions and cranial mass | Yes (48) |
| Shahidi et al. 2011 [12] | 20 M | Perianal wounds (1 year) | Well demarcated erythematous plaque | Difficulty in defecation | Antibiotics and steroids | None | None | Thalidomide | Lesion shrunk and became painless | Yes (6) |
| Waters et al. 2015 [13] | 32 M | Perianal ulcerations (10 years), multiple excisions, and biopsies | Obliteration of anal verge by scar tissue | Pain and pressure | Laparoscopic diverting colostomy | None | None | None | – | – |
| Madnani et al. 2011 [14] | 38 F | Polydipsia (8 years), vulvar ulcers (5 years) | Demarcated, indurated ulcer labia minora extending to the perianal area | – | Antibiotics multiple biopsies | 0 | Liver, bone, DI, mass in brain ventricle on brain MRI | Etoposide, 6-mercaptopurine, prednisolone | Bone pain disappeared, skin lesions healed | Yes (120) |
| Conias et al. 1998 [15] | 24 M | Scalp scaling and external auditory canal discharge and crusting (4 years) | Ulcerated hemorrhagic plaque extending to the scrotum (pain and bleeding) | – | Potassium permanganate, topical steroids, local radiotherapy | None | None | Cladribine | Scalp and ear lesions disappeared. Perianal lesions recurred and responded to local radiotherapy | Yes (12) |
| Field et al. 2007 [13] | 70 M | Perianal pain and discharge (4 M), prostate CA | 2-cm ulcerated lesion | Rectal bleeding, pain, mucous discharge | Steroids, potassium permanganate | After the perianal lesions | Tibial lesion | – | – | – |
| Broekaert et al. 2007 [17] | 57 F | Polydipsia (2 years), inguinal and perianal ulcers (1 year) | Ulcerations with red raised border | None, only systemic | 0 | DL thickened infundibulum on brain MRI | Thalidomide | Skin lesions healed; cerebral lesion remained stable | Yes (24) |
| Author, year | Age in years, sex | History | Perianal lesion morphology | Perianal lesion symptoms | Perianal lesion treatment | Interval* | Systemic involvement | Systemic treatment | Treatment outcome | Survival (follow-up time in months) |
|--------------|------------------|---------|-----------------------------|--------------------------|--------------------------|-----------|---------------------|-----------------|------------------|----------------------------------|
| Roeb et al. 2012 | 69 M | Perianal fistula, eczema, abdominal pain (4 years) | – | Perianal pain | Steroids | 0 | Colon (mucosal lesions throughout) | – | Perianal eczema and abdominal pain improved | – |
| This patient presentation | 50 M | Polydipsia (3 years), perianal ulcers and pruritus ani (1 year) | Excoriated and erythematous, multiple superficial lacerations | Pruritus and pain | Silver sulfadiazine, zinc oxide | None | DI (no masses on brain MRI) | None | None | Yes |

* data not reported; Interval*, interval time between LCH lesions pathological diagnosis and systematic manifestation; APR, abdominal perineal resection; DI, diabetes insipidus; MTX, Methotrexate; NSGY, Neurosurgery; CT, Computed Tomography
Limitations
This case report and patient is limited by the lack of surgical and oncological follow-up, which is far too prevalent in patients living in underserved communities. Fortunately, this patient's disease remained stable, but the lack of appropriate care can lead to patients presenting with advanced disease that is seldom seen, otherwise. Ideally, the patient would have been seen in the colorectal clinic within a month of his colonoscopy and perianal inflammation findings that prompted his referral. He would have also been able to obtain a repeat biopsy, and then receive imiquimod treatment with close surgical and oncologic follow-up.

Learning points:

- A history of diabetes insipidus in a patient with a rash should raise a high index of suspicion, and the rash should be biopsied.
- LCH can disseminate into internal organs with a dismal prognosis, or it can be limited to a cutaneous lesion with a benign clinical course. Close follow-up is warranted to monitor progression.
- Caring for patients living in an underserved community adds a layer of complexity. Efforts should be done to track patients and facilitate appropriate follow-up.

Abbreviations
LCH: Langerhans cell histiocytosis; DI: Diabetes insipidus; MRI: Magnetic resonance imaging; PET: Positron emission tomography; LC: Langerhans cell; LCS: Langerhans cell sarcoma; SS-LCH: Single-system Langerhans cell histiocytosis; MS-LCH: Multisystem Langerhans cell histiocytosis.

Acknowledgements
Not applicable.

Authors’ contributions
VF examined, diagnosed, and managed the patient. JQ analyzed the pathology slides and provided pathology figures. MH reviewed the existing literature and drafted the paper. JQ and VF critically revised the manuscript for submission. All authors read and approved the final manuscript.

Funding
The authors have no sources of funding to declare.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
No ethics approval was required for the drafting of this report.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that there is no conflict of interest regarding the publication of this article.

Author details
1 Departments of Surgery, Texas Tech University Health Sciences Center, El Paso, TX, USA. 2 Pathology at Texas Tech University Health Sciences Center, El Paso, TX, USA.

Received: 20 January 2021   Accepted: 24 May 2021
Published online: 22 July 2021

References
1. Rizzo FM, Cives M, Simone V, Silvestris F. New insights into the molecular pathogenesis of Langerhans cell histiocytosis. Oncologist. 2014;19(2):151–63. https://doi.org/10.1634/theoncologist.2013-0341.
2. Abdou AG, MaherTaie D. Perianal Langerhans cell histiocytosis: a rare presentation in an adult male. Autops Case Rep. 2017;7(3):38–43. https://doi.org/10.4322/acr.2017.028.
3. Tugemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DALK-HX-83- and 90-study. Med Pediatr Oncol. 2001;37(2):108–14. https://doi.org/10.1002/mpo.1178 (PMID: 11496348).
4. Harmon CM, Brown N. Langerhans cell histiocytosis: a clinicopathologic review and molecular pathogenetic update. Arch Pathol Lab Med. 2015;139(10):1211–4. https://doi.org/10.5858/arpa.2015-0199-RA.
5. Mansour M, Mobek E, Fares E, et al. Adult Langerhans cell histiocytosis with pulmonary and colorectal involvement: a case report. J Med Case Rep. 2017;11:272. https://doi.org/10.1186/s13256-017-1426-7.
6. Gu 0Q, Sisman P, Cander S, et al. An unusual case of adult-onset multisystemic Langerhans cell histiocytosis with perianal and incident thyroid involvement. Endocrinol Diabetes Metab Case Rep. 2017;2017:16–0087. https://doi.org/10.1530/EDM-16-0087.
7. Bank A, Christensen C. Unusual manifestation of Langerhans’ cell histiocytosis. Acta Med Scand. 1988;223(5):479–80. https://doi.org/10.1111/j.1365-2133.2008.08934.x.
8. Dore Y, Šahn C, Čeklik SY, Čeklik OI, Kara A, Doğan G. Perianal presentation of Langerhans cell histiocytosis. Dermatol Sin. 2016;34(2):99–101. https://doi.org/10.1110/jdsi.2015.09.003.
9. Chauffaille Mde L, Valério RM, Diniz CM, et al. Langerhans cell histiocytosis: an uncommon presentation, successfully treated by thalidomide. Indian J Dermatol Venereol Leprol. 2011;77(5):587–90. https://doi.org/10.4103/0378-6323.84064.
10. Mittal T, Davis MD, Lundell RB. Perianal Langerhans cell histiocytosis was relieved by surgical excision. Br J Dermatol. 2009;160(1):213–5. https://doi.org/10.1111/j.1365-2133.2008.08934.x.
11. Foster A, Epanomeritakis M, Moorehead J. Langerhans cell histiocytosis of the perianal region. Ulster Med J. 2003;72(1):50–1.
12. Shahidi-Dadras M, Saeedi M, Shokeri S, Ayatollahi A. Langerhans cell histiocytosis: an uncommon presentation, successfully treated by thalidomide. Indian J Dermatol Venereol Leprol. 2011;77(5):587–90. https://doi.org/10.4103/0378-6323.84064.
13. Waters J, Fajardo A, Holcomb B, et al. Langerhans cell histiocytosis with anorectal involvement: a rare manifestation of adult disease. Int J Colorectal Dis. 2015;30:707–8. https://doi.org/10.1007/s00384-014-2033-5.
14. Madnani NA, Khan KJ. Vulvar ulcer as a presentation of systemic Langerhans cell histiocytosis. Indian J Dermatol Venereol Leprol. 2011;77(2):177–9. https://doi.org/10.4103/0378-6323.74758.
15. Conias S, Strutton G, Stephenson G. Adult cutaneous Langerhans cell histiocytosis. Australas J Dermatol. 1998;39:106–8. https://doi.org/10.1111/j.1440-0960.1998.tb01259.x.
16. Field M, Inston N, Muzzaffer S, et al. Perianal Langerhans cell histiocytosis. Int J Colorectal Dis. 2007;22:1141–2. https://doi.org/10.1007/s00384-006-0147-0.
17. Broekaert SM, Metzler G, Burgdorf W, Röcken M, Schaller M. Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide. Am J Clin Dermatol. 2007;8(5):311–4. https://doi.org/10.2165/00128071-200708050-00007.

18. Ploeb E, Etschmann B, Gattenlöhn B, S. Is it always Crohn’s disease in a patient with perianal fistulae and skip lesions in the colon? Gastroenterology. 2012;143(1):e7–8. https://doi.org/10.1053/j.gastro.2011.12.013.

19. Rao DG, Trivedi MV, Havale R, Shrutha P. A rare and unusual case report of Langerhans cell histiocytosis. J Oral Maxillofac Pathol. 2017;21(1):140–4. https://doi.org/10.4103/jomfp.JOMFP_10_17.

20. Aricò M, Girschikofsky M, Genéreau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Jui E, Danesino C. Langerhans cell histiocytosis in adults: Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39(6):2341–8. https://doi.org/10.1016/s0959-8049(03)00672-5.

21. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26–35. https://doi.org/10.1182/blood-2014-12-669301.

22. Nakamine H, Yamakawa M, Yoshino T, Fukumoto T, Enomoto Y, Matsumura I. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematol. 2016;56(2):109–18. https://doi.org/10.3960/jjshr.56.109.

23. Kawase T, Hamazaki M, Ogura M, et al. CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol. 2005;81:323–9. https://doi.org/10.1532/IJH97.04142.

24. Zhao G, Luo M, Wu ZY, et al. Langerhans cell sarcoma involving gall-bladder and peritoneal lymph nodes: a case report. Int J Surg Pathol. 2009;17(4):347–53. https://doi.org/10.1177/1066896908324128.

25. Bohn OL, Ruiz-Arreguiles G, Navarro L, Saldivar J, Sanchez-Sosa S. Cutaneous Langerhans cell sarcoma: a case report and review of the literature. Int J Hematol. 2007;2007(85):116–20.

26. Li Y, Li B, Tian X, Li Z. Unusual cutaneous Langerhans cell sarcoma without extracutaneous involvement. Diagn Pathol. 2013;8:20. https://doi.org/10.1186/1746-1596-8-20.

27. Tella SH, Kommalapati A, Rech KL, Go RS, Goyal G. Incidence, clinical features, and outcomes of Langerhans cell sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019;19(7):441–6. https://doi.org/10.1016/j.clml.2019.03.026.

28. Yi W, Chen WY, Yang TX, Lan JP, Liang WN. Langerhans cell sarcoma arising from antecedent Langerhans cell histiocytosis: a case report. Medicine (Baltimore). 2019;98(10):e14531. https://doi.org/10.1097/MD.0000000000014531.

29. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, DeSios G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, Isaacson PG, Jaffe ES, Klunen P, Knowles DM, Mason DY, Mon S, Muller-Hermelink HK, Piris MA, Ralfkiaer E, Stein H, Su I, Warnke RA, Weiss LM. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41(1):1–29. https://doi.org/10.1046/j.1365-2559.2002.01418.x.

30. Prosch H, Grois N, Prayer D, Waldhauser F, Steiner M, Minkov M, Gadner H. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:594–9. https://doi.org/10.1002/pbc.20102.

31. Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, Tinelli C, Gallucci M, Bernasconi S, Boschenini B, Severi F, Ancic M. Central diabetes insipidus in children and young adults. N Engl J Med. 2003;349:1998–2007. https://doi.org/10.1056/NEJM200010053431403.

32. Grois N, Prayer D, Prosch H, Minkov M, Potschger U, Gadner H. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:59–65. https://doi.org/10.1002/pbc.20003.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.